---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057745"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:41:39.690903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q3 net loss $177M; acoramidis NDA filing by year-end

## Summary
- Net loss attributable to common stockholders $177M ($1.08 per share) vs $137M ($0.93) YoY.
- Revenue $4.1M, up from $0.3M YoY; operating costs $161.8M vs $129.5M.
- Cash, equivalents, marketable securities $505.2M; raised $316M gross via ATM and PIPE.
- NDA for acoramidis (ATTR-CM) to be filed with FDA by end of 2023; Phase 3 win ratio 1.8 (p<0.0001).
- Regulatory alignment with FDA/EMA for infigratinib in achondroplasia; Phase 3 trial start expected in 2023.

## SEC filing metadata
- accession: 0000950170-23-057745
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/0000950170-23-057745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/bbio-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057745
- JSON: https://secwatch.observer/filing/0000950170-23-057745.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057745.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/0000950170-23-057745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.